"10.1371_journal.pone.0050716","plos one","2012-12-17T00:00:00Z","Dennis L Kelleher; Rashmi S Mehta; Bernadette M Jean-Francois; Andrew F Preece; James Blowers; Glenn D Crater; Paul Thomas","Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America; GlaxoSmithKline Australia Pty Ltd, Melbourne, Australia; Respiratory Medicines Development Center, GlaxoSmithKline, Stockley Park West, United Kingdom; GlaxoSmithKline, Mississauga, Canada; Medicines Research Unit, GlaxoSmithKline, New South Wales, Australia","Conceived and designed the experiments: DK RM AP GC. Performed the experiments: BJF AP PT. Analyzed the data: DK RM AP JB GC PT. Wrote the paper: DK RM BJF AP JB GC PT.","DK, RM, BJF, AP, JB and GC are full time employees and own stock in GlaxoSmithKline. PT was a contract medical monitor employed by GlaxoSmithKline during this study. Editorial support (in the form of writing assistance, assembling tables and figures, collating author comments, grammatical editing and referencing) was provided by Gloria Boone M.S., M.BA. and Lawrence Boone Ph.D., Boone Consulting Services, Fuquay Varina, North Carolina, United States of America and was funded by GlaxoSmithKline. GlaxoSmithKline has patents and patent applications that cover umeclidinium, vilanterol and the combination of umeclidinium and vilanterol. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","Dennis L Kelleher","DLK",7,TRUE,4,3,6,7,TRUE,TRUE,FALSE,0,NA,FALSE
